{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:50:49Z","timestamp":1791255049106,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11060-026-05800-3","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:06:58Z","timestamp":1791191218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma"],"prefix":"10.1007","volume":"180","author":[{"given":"Anita L.","family":"Kalluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Rakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Weber-Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyaansh","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Materi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisa C.","family":"Schreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Aldecoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Holdhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Weingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep J. Gonz\u00e1lez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordina","family":"Rincon-Torroella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"1","key":"5800_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11060-024-04829-6","volume":"171","author":"J Rincon-Torroella","year":"2025","unstructured":"Rincon-Torroella J, Rakovec M, Kalluri AL et al (2025) Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ. J Neurooncol 171(1):35\u201345. https:\/\/doi.org\/10.1007\/s11060-024-04829-6","journal-title":"J Neurooncol"},{"key":"5800_CR2","doi-asserted-by":"publisher","first-page":"934426","DOI":"10.3389\/fonc.2022.934426","volume":"12","author":"J Rincon-Torroella","year":"2022","unstructured":"Rincon-Torroella J, Rakovec M, Materi J et al (2022) Current and Future Frontiers of Molecularly Defined Oligodendrogliomas. Front Oncol 12:934426. https:\/\/doi.org\/10.3389\/fonc.2022.934426","journal-title":"Front Oncol"},{"issue":"6","key":"5800_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl) 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol (Berl)"},{"issue":"8","key":"5800_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"key":"5800_CR5","doi-asserted-by":"publisher","unstructured":"Garton ALA, Kinslow CJ, Rae AI et al (2020) Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. Published online May 8. https:\/\/doi.org\/10.3171\/2020.2.JNS192767","DOI":"10.3171\/2020.2.JNS192767"},{"issue":"5","key":"5800_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/cns.15.26","volume":"4","author":"N Thon","year":"2015","unstructured":"Thon N, Kreth FW, Tonn JC (2015) The role of surgery in grade II\/III oligodendroglial tumors. CNS Oncol 4(5):317\u2013323. https:\/\/doi.org\/10.2217\/cns.15.26","journal-title":"CNS Oncol"},{"issue":"4","key":"5800_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1227\/01.NEU.0000325729.41085.73","volume":"63","author":"MJ McGirt","year":"2008","unstructured":"McGirt MJ, Chaichana KL, Attenello FJ et al (2008) Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63(4):700\u2013707. https:\/\/doi.org\/10.1227\/01.NEU.0000325729.41085.73","journal-title":"Neurosurgery"},{"issue":"8","key":"5800_CR8","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","volume":"26","author":"JS Smith","year":"2008","unstructured":"Smith JS, Chang EF, Lamborn KR et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol Off J Am Soc Clin Oncol 26(8):1338\u20131345. https:\/\/doi.org\/10.1200\/JCO.2007.13.9337","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"5800_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1023\/a:1005715405413","volume":"34","author":"MS Berger","year":"1997","unstructured":"Berger MS, Rostomily RC (1997) Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 34(1):85\u2013101. https:\/\/doi.org\/10.1023\/a:1005715405413","journal-title":"J Neurooncol"},{"key":"5800_CR10","doi-asserted-by":"publisher","unstructured":"Kavouridis VK, Boaro A, Dorr J et al (2019) Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. Published online Oct 25. https:\/\/doi.org\/10.3171\/2019.6.JNS19972","DOI":"10.3171\/2019.6.JNS19972"},{"issue":"3","key":"5800_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5800_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski C, Nabors LB, Portnow J et al (2023) NCCN Guidelines\u00ae Insights: Central Nervous System Cancers, Version 2.2022: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 21(1):12\u201320. https:\/\/doi.org\/10.6004\/jnccn.2023.0002","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"5800_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT et al (2022) Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol Off J Am Soc Clin Oncol 40(4):403\u2013426. https:\/\/doi.org\/10.1200\/JCO.21.02036","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"5800_CR14","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","volume":"28","author":"AS Jakola","year":"2017","unstructured":"Jakola AS, Skjulsvik AJ, Myrmel KS et al (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol Off J Eur Soc Med Oncol 28(8):1942\u20131948. https:\/\/doi.org\/10.1093\/annonc\/mdx230","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"18","key":"5800_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/jama.2012.12807","volume":"308","author":"AS Jakola","year":"2012","unstructured":"Jakola AS, Myrmel KS, Kloster R et al (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308(18):1881\u20131888. https:\/\/doi.org\/10.1001\/jama.2012.12807","journal-title":"JAMA"},{"issue":"1","key":"5800_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/nox176","volume":"20","author":"MMJ Wijnenga","year":"2018","unstructured":"Wijnenga MMJ, French PJ, Dubbink HJ et al (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncol 20(1):103\u2013112. https:\/\/doi.org\/10.1093\/neuonc\/nox176","journal-title":"Neuro-Oncol"},{"issue":"4","key":"5800_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3171\/2016.11.JNS161974","volume":"128","author":"AA Alattar","year":"2018","unstructured":"Alattar AA, Brandel MG, Hirshman BR et al (2018) Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Neurosurg 128(4):1076\u20131083. https:\/\/doi.org\/10.3171\/2016.11.JNS161974","journal-title":"J Neurosurg"},{"issue":"3","key":"5800_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11060-024-04883-0","volume":"171","author":"AL Kalluri","year":"2025","unstructured":"Kalluri AL, Lee JH, Lucas CHG, Rincon-Torroella J, Bettegowda C (2025) Implications of molecular classifications in glioma surgery. J Neurooncol 171(3):559\u2013569. https:\/\/doi.org\/10.1007\/s11060-024-04883-0","journal-title":"J Neurooncol"},{"issue":"9","key":"5800_CR19","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","volume":"25","author":"P Karschnia","year":"2024","unstructured":"Karschnia P, Gerritsen JKW, Teske N et al (2024) The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group. Lancet Oncol 25(9):e404\u2013e419. https:\/\/doi.org\/10.1016\/S1470-2045(24)00130-X","journal-title":"Lancet Oncol"},{"issue":"11","key":"5800_CR20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/JCO.21.02929","volume":"41","author":"SL Hervey-Jumper","year":"2023","unstructured":"Hervey-Jumper SL, Zhang Y, Phillips JJ et al (2023) Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol Off J Am Soc Clin Oncol 41(11):2029\u20132042. https:\/\/doi.org\/10.1200\/JCO.21.02929","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"5800_CR21","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1158\/1078-0432.CCR-24-0901","volume":"30","author":"T van der Vaart","year":"2024","unstructured":"van der Vaart T, Wijnenga MMJ, van Garderen K et al (2024) Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study. Clin Cancer Res Off J Am Assoc Cancer Res 30(17):3837\u20133844. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0901","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"5800_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-018-2985-3","volume":"140","author":"X Ding","year":"2018","unstructured":"Ding X, Wang Z, Chen D et al (2018) The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. J Neurooncol 140(3):591\u2013603. https:\/\/doi.org\/10.1007\/s11060-018-2985-3","journal-title":"J Neurooncol"},{"issue":"2","key":"5800_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00330-023-10125-0","volume":"34","author":"YW Park","year":"2024","unstructured":"Park YW, Kim S, Han K et al (2024) Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification. Eur Radiol 34(2):1376\u20131387. https:\/\/doi.org\/10.1007\/s00330-023-10125-0","journal-title":"Eur Radiol"},{"issue":"3","key":"5800_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-019-03261-5","volume":"144","author":"CJ Kinslow","year":"2019","unstructured":"Kinslow CJ, Garton ALA, Rae AI et al (2019) Extent of resection and survival for oligodendroglioma: a U.S. population-based study. J Neurooncol 144(3):591\u2013601. https:\/\/doi.org\/10.1007\/s11060-019-03261-5","journal-title":"J Neurooncol"},{"issue":"1","key":"5800_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11060-018-03030-w","volume":"141","author":"D Delev","year":"2019","unstructured":"Delev D, Heiland DH, Franco P et al (2019) Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol 141(1):223\u2013233. https:\/\/doi.org\/10.1007\/s11060-018-03030-w","journal-title":"J Neurooncol"},{"issue":"1","key":"5800_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-023-04368-6","volume":"164","author":"L Carstam","year":"2023","unstructured":"Carstam L, Latini F, Solheim O et al (2023) Long-term follow up of patients with WHO grade 2 oligodendroglioma. J Neurooncol 164(1):65\u201374. https:\/\/doi.org\/10.1007\/s11060-023-04368-6","journal-title":"J Neurooncol"},{"issue":"7624","key":"5800_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD","journal-title":"BMJ"},{"issue":"2","key":"5800_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jamcollsurg.2017.11.005","volume":"226","author":"S Subramaniam","year":"2018","unstructured":"Subramaniam S, Aalberg JJ, Soriano RP, Divino CM (2018) New 5-Factor Modified Frailty Index Using American College of Surgeons NSQIP Data. J Am Coll Surg 226(2):173\u2013181e8. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.11.005","journal-title":"J Am Coll Surg"},{"issue":"12","key":"5800_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S1470-2045(25)00534-0","volume":"26","author":"P Karschnia","year":"2025","unstructured":"Karschnia P, Young JS, Wijnenga MMJ et al (2025) A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group. Lancet Oncol 26(12):1638\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(25)00534-0","journal-title":"Lancet Oncol"},{"issue":"6","key":"5800_CR30","doi-asserted-by":"publisher","first-page":"e4731","DOI":"10.1002\/nbm.4731","volume":"36","author":"S Jiang","year":"2023","unstructured":"Jiang S, Wen Z, Ahn SS et al (2023) Applications of chemical exchange saturation transfer MRI in identifying genetic markers in gliomas. NMR Biomed 36(6):e4731. https:\/\/doi.org\/10.1002\/nbm.4731","journal-title":"NMR Biomed"},{"issue":"8","key":"5800_CR31","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1158\/1078-0432.CCR-18-3101","volume":"25","author":"JB Iorgulescu","year":"2019","unstructured":"Iorgulescu JB, Torre M, Harary M et al (2019) The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res Off J Am Assoc Cancer Res 25(8):2656\u20132663. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3101","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"5800_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol Off J Am Soc Clin Oncol 31(3):337\u2013343. https:\/\/doi.org\/10.1200\/JCO.2012.43.2674","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"5800_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol Off J Am Soc Clin Oncol 31(3):344\u2013350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"35","key":"5800_CR34","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","volume":"27","author":"W Wick","year":"2009","unstructured":"Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol Off J Am Soc Clin Oncol 27(35):5874\u20135880. https:\/\/doi.org\/10.1200\/JCO.2009.23.6497","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"5800_CR35","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol 22(8):1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neuro-Oncol"},{"issue":"12","key":"5800_CR36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/neuonc\/noad133","volume":"25","author":"JS Young","year":"2023","unstructured":"Young JS, Morshed RA, Hervey-Jumper SL, Berger MS (2023) The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions. Neuro-Oncol 25(12):2117\u20132133. https:\/\/doi.org\/10.1093\/neuonc\/noad133","journal-title":"Neuro-Oncol"},{"key":"5800_CR37","doi-asserted-by":"publisher","first-page":"123716","DOI":"10.1016\/j.wneu.2025.123716","volume":"196","author":"K Jiang","year":"2025","unstructured":"Jiang K, Kalluri A, Odonkor M et al (2025) Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study. World Neurosurg 196:123716. https:\/\/doi.org\/10.1016\/j.wneu.2025.123716","journal-title":"World Neurosurg"},{"issue":"7","key":"5800_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med 389(7):589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"key":"5800_CR39","doi-asserted-by":"publisher","unstructured":"McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 65(3):463\u2013469; discussion 469\u2013470. https:\/\/doi.org\/10.1227\/01.NEU.0000349763.42238.E9","DOI":"10.1227\/01.NEU.0000349763.42238.E9"},{"issue":"3","key":"5800_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10014-018-0324-1","volume":"35","author":"S Koriyama","year":"2018","unstructured":"Koriyama S, Nitta M, Kobayashi T et al (2018) A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis. Brain Tumor Pathol 35(3):159\u2013167. https:\/\/doi.org\/10.1007\/s10014-018-0324-1","journal-title":"Brain Tumor Pathol"},{"issue":"3","key":"5800_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3171\/2010.6.JNS091246","volume":"114","author":"EF Chang","year":"2011","unstructured":"Chang EF, Clark A, Smith JS et al (2011) Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg 114(3):566\u2013573. https:\/\/doi.org\/10.3171\/2010.6.JNS091246","journal-title":"J Neurosurg"},{"issue":"1","key":"5800_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1056\/NEJMoa067819","volume":"358","author":"N Sanai","year":"2008","unstructured":"Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358(1):18\u201327. https:\/\/doi.org\/10.1056\/NEJMoa067819","journal-title":"N Engl J Med"},{"issue":"1","key":"5800_CR43","doi-asserted-by":"publisher","first-page":"CD009685","DOI":"10.1002\/14651858.CD009685.pub2","volume":"2014","author":"DG Barone","year":"2014","unstructured":"Barone DG, Lawrie TA, Hart MG (2014) Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev 2014(1):CD009685. https:\/\/doi.org\/10.1002\/14651858.CD009685.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5800_CR44","doi-asserted-by":"publisher","unstructured":"Mohammadi AM, Sullivan TB, Barnett GH et al (2014) Use of high-field intraoperative magnetic resonance imaging to enhance the extent of resection of enhancing and nonenhancing gliomas. Neurosurgery.;74(4):339\u2013348; discussion 349; quiz 349\u2013350. https:\/\/doi.org\/10.1227\/NEU.0000000000000278","DOI":"10.1227\/NEU.0000000000000278"},{"issue":"1","key":"5800_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1227\/neu.0000000000002612","volume":"94","author":"SA Sattari","year":"2024","unstructured":"Sattari SA, Rincon-Torroella J, Sattari AR et al (2024) Awake Versus Asleep Craniotomy for Patients With Eloquent Glioma: A Systematic Review and Meta-Analysis. Neurosurgery 94(1):38\u201352. https:\/\/doi.org\/10.1227\/neu.0000000000002612","journal-title":"Neurosurgery"},{"issue":"2","key":"5800_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/01.NCC.0000305699.97625.dc","volume":"31","author":"A Palese","year":"2008","unstructured":"Palese A, Skrap M, Fachin M, Visioli S, Zannini L (2008) The experience of patients undergoing awake craniotomy: in the patients\u2019 own words. A qualitative study. Cancer Nurs 31(2):166\u2013172. https:\/\/doi.org\/10.1097\/01.NCC.0000305699.97625.dc","journal-title":"Cancer Nurs"},{"issue":"7","key":"5800_CR47","doi-asserted-by":"publisher","first-page":"e047306","DOI":"10.1136\/bmjopen-2020-047306","volume":"11","author":"JKW Gerritsen","year":"2021","unstructured":"Gerritsen JKW, Dirven CMF, De Vleeschouwer S et al (2021) The PROGRAM study: awake mapping versus asleep mapping versus no mapping for high-grade glioma resections: study protocol for an international multicenter prospective three-arm cohort study. BMJ Open 11(7):e047306. https:\/\/doi.org\/10.1136\/bmjopen-2020-047306","journal-title":"BMJ Open"},{"issue":"4","key":"5800_CR48","doi-asserted-by":"publisher","first-page":"e082274","DOI":"10.1136\/bmjopen-2023-082274","volume":"14","author":"JKW Gerritsen","year":"2024","unstructured":"Gerritsen JKW, Young JS, Chang SM et al (2024) SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201). BMJ Open 14(4):e082274. https:\/\/doi.org\/10.1136\/bmjopen-2023-082274","journal-title":"BMJ Open"},{"issue":"33","key":"5800_CR49","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol Off J Am Soc Clin Oncol 41(33):5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"5800_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1215\/S1152851703000620","volume":"6","author":"KR Lamborn","year":"2004","unstructured":"Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol 6(3):227\u2013235. https:\/\/doi.org\/10.1215\/S1152851703000620","journal-title":"Neuro-Oncol"},{"issue":"1","key":"5800_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-017-2559-9","volume":"135","author":"F Pessina","year":"2017","unstructured":"Pessina F, Navarria P, Cozzi L et al (2017) Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 135(1):129\u2013139. https:\/\/doi.org\/10.1007\/s11060-017-2559-9","journal-title":"J Neurooncol"},{"issue":"4","key":"5800_CR52","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3171\/2013.12.JNS13184","volume":"120","author":"ME Oppenlander","year":"2014","unstructured":"Oppenlander ME, Wolf AB, Snyder LA et al (2014) An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg 120(4):846\u2013853. https:\/\/doi.org\/10.3171\/2013.12.JNS13184","journal-title":"J Neurosurg"},{"issue":"5","key":"5800_CR53","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3171\/2012.8.JNS12234","volume":"117","author":"D Orringer","year":"2012","unstructured":"Orringer D, Lau D, Khatri S et al (2012) Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 117(5):851\u2013859. https:\/\/doi.org\/10.3171\/2012.8.JNS12234","journal-title":"J Neurosurg"},{"issue":"1","key":"5800_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/neuonc\/not137","volume":"16","author":"KL Chaichana","year":"2014","unstructured":"Chaichana KL, Jusue-Torres I, Navarro-Ramirez R et al (2014) Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncol 16(1):113\u2013122. https:\/\/doi.org\/10.1093\/neuonc\/not137","journal-title":"Neuro-Oncol"},{"issue":"3","key":"5800_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.24.00049","volume":"43","author":"SEO Kacimi","year":"2025","unstructured":"Kacimi SEO, Dehais C, Feuvret L et al (2025) Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p\/19q-Codeleted Grade 3 Oligodendroglioma. J Clin Oncol Off J Am Soc Clin Oncol 43(3):329\u2013338. https:\/\/doi.org\/10.1200\/JCO.24.00049","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"5800_CR56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11060-021-03765-z","volume":"153","author":"J Weller","year":"2021","unstructured":"Weller J, Katzendobler S, Karschnia P et al (2021) PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. J Neurooncol 153(2):283\u2013291. https:\/\/doi.org\/10.1007\/s11060-021-03765-z","journal-title":"J Neurooncol"},{"issue":"3","key":"5800_CR57","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-021-03781-z","volume":"153","author":"NAO Bush","year":"2021","unstructured":"Bush NAO, Young JS, Zhang Y et al (2021) A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol 153(3):447\u2013454. https:\/\/doi.org\/10.1007\/s11060-021-03781-z","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05800-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:02:07Z","timestamp":1791252127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5800"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05800-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board approval was received prior to initiating this institutional retrospective cohort study with a waiver granted for informed patient consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed following the STROBE guidelines for the reporting of observational studies.","order":2,"name":"Ethics","label":"Reporting guidelines","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Preliminary findings from this study were presented as a poster at the 2023 European Association of Neurosurgical Societies (EANS) and 2023 Congress of Neurological Surgeons annual meetings. No portion of this paper has been previously published in any format. This paper is one of a series of studies on oligodendroglioma completed by our group.","order":3,"name":"Ethics","label":"Previous presentations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CB is a consultant for Haystack Oncology and Privo Technologies. CB is a co-founder of OrisDx and Belay Diagnostics. HB is a consultant for Candel Therapeutics Inc., CraniUS Inc., and Nurami Medical. HB receives research funding from the NIH, Johns Hopkins University, Intragel Therapeutics, the Khatib Foundation, and philanthropy.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"4"}}